105 related articles for article (PubMed ID: 16962673)
1. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.
Rath GM; Schneider C; Dedieu S; Rothhut B; Soula-Rothhut M; Ghoneim C; Sid B; Morjani H; El Btaouri H; Martiny L
Biochim Biophys Acta; 2006 Oct; 1763(10):1125-34. PubMed ID: 16962673
[TBL] [Abstract][Full Text] [Related]
2. Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.
El Btaouri H; Morjani H; Greffe Y; Charpentier E; Martiny L
Biochim Biophys Acta; 2011 May; 1813(5):695-703. PubMed ID: 21333695
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 induces differential response in human corneal and conjunctival epithelial cells lines under in vitro inflammatory and apoptotic conditions.
Soriano-Romaní L; García-Posadas L; López-García A; Paraoan L; Diebold Y
Exp Eye Res; 2015 May; 134():1-14. PubMed ID: 25753839
[TBL] [Abstract][Full Text] [Related]
4. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma.
Rath G; Schneider C; Langlois B; Sartelet H; Morjani H; Btaouri HE; Dedieu S; Martiny L
Int J Biochem Cell Biol; 2009 May; 41(5):1165-72. PubMed ID: 19027085
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.
Soula-Rothhut M; Coissard C; Sartelet H; Boudot C; Bellon G; Martiny L; Rothhut B
Exp Cell Res; 2005 Mar; 304(1):187-201. PubMed ID: 15707585
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.
Sid B; Langlois B; Sartelet H; Bellon G; Dedieu S; Martiny L
Int J Biochem Cell Biol; 2008; 40(9):1890-900. PubMed ID: 18321763
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway.
Rath GM; Schneider C; Dedieu S; Sartelet H; Morjani H; Martiny L; El Btaouri H
Int J Biochem Cell Biol; 2006; 38(12):2219-28. PubMed ID: 16971166
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells.
Courageot MP; Duca L; Martiny L; Devarenne-Charpentier E; Morjani H; El Btaouri H
Front Oncol; 2020; 10():551228. PubMed ID: 33365267
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells.
Massart C; Barbet R; Genetet N; Gibassier J
Thyroid; 2004 Apr; 14(4):263-70. PubMed ID: 15142359
[TBL] [Abstract][Full Text] [Related]
10. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis.
Salajegheh M; Raju R; Schmidt J; Dalakas MC
J Neuroimmunol; 2007 Jul; 187(1-2):166-74. PubMed ID: 17572512
[TBL] [Abstract][Full Text] [Related]
12. Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.
Saumet A; Slimane MB; Lanotte M; Lawler J; Dubernard V
Blood; 2005 Jul; 106(2):658-67. PubMed ID: 15784731
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.
Scarpino S; Di Napoli A; Taraboletti G; Cancrini A; Ruco LP
J Pathol; 2005 Jan; 205(1):50-6. PubMed ID: 15526350
[TBL] [Abstract][Full Text] [Related]
14. Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study.
Floquet N; Dedieu S; Martiny L; Dauchez M; Perahia D
Arch Biochem Biophys; 2008 Oct; 478(1):103-9. PubMed ID: 18675774
[TBL] [Abstract][Full Text] [Related]
15. Escherichia coli K1 promotes the ligation of CD47 with thrombospondin-1 to prevent the maturation of dendritic cells in the pathogenesis of neonatal meningitis.
Mittal R; Gonzalez-Gomez I; Prasadarao NV
J Immunol; 2010 Sep; 185(5):2998-3006. PubMed ID: 20675593
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 receptor mediates autophagy of RAS-expressing cancer cells and triggers tumour growth inhibition.
Kalas W; Swiderek E; Switalska M; Wietrzyk J; Rak J; Strzadala L
Anticancer Res; 2013 Apr; 33(4):1429-38. PubMed ID: 23564783
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines.
Yamanaka T; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Ito M; Takase K; Moriyama M; Nakano T; Suzuki A
Hepatology; 2000 Sep; 32(3):482-90. PubMed ID: 10960439
[TBL] [Abstract][Full Text] [Related]
18. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.
Quesada AJ; Nelius T; Yap R; Zaichuk TA; Alfranca A; Filleur S; Volpert OV; Redondo JM
Cell Death Differ; 2005 Jun; 12(6):649-58. PubMed ID: 15818399
[TBL] [Abstract][Full Text] [Related]
19. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.
Lih CJ; Wei W; Cohen SN
Genes Dev; 2006 Aug; 20(15):2082-95. PubMed ID: 16847352
[TBL] [Abstract][Full Text] [Related]
20. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
